 |
|
Differential Access in the Receipt of Antiretroviral Drugs for the Treatment of AIDS and Its Implications for Survival
Kathryn H. Anderson, PhD;
Jean M. Mitchell, PhD
Arch Intern Med. 2000;160:3114-3120.
Background Recently published research based on selected samples of patients treated at human immunodeficiency virus clinics documents that use of more intensive antiretroviral drug therapies is responsible for significant declines in morbidity and mortality in persons living with human immunodeficiency virus or acquired immunodeficiency syndrome (PLWHAs). In this study, we evaluate whether receipt of more recently developed antiretroviral therapies varies by sex and race/ethnicity in a large population-based sample of PLWHAs and whether receipt of such drugs has any impact on survival.
Methods Analysis of Florida Medicaid eligibility, enrollment, and claims data for PLWHAs for 1993 through 1997. Receipt of 2 nucleoside analogs (TWONUKES) and receipt of 1 protease inhibitor and a nucleoside combination (PI+NUKES) was constructed from claims data. The probability of dying was constructed from eligibility and enrollment data.
Results The probabilities of receiving TWONUKES and PI+NUKES are 0.16 and 0.09, respectively, lower for women relative to men (P<.01 for both). Blacks are more likely to receive TWONUKES than whites, whereas the reverse is true for Hispanics; this probability is almost 0.04 higher for blacks and 0.03 lower for Hispanics relative to whites (P<.01). In contrast, blacks are significantly less likely to receive PI+NUKES (P<.01). Both drug variables have large statistically significant negative effects on the probability of death. The PLWHAs who received PI+NUKES are 60% as likely to die each month (P<.01). Receipt of TWONUKES lowers the relative hazard of death by close to 66% each month (P<.01). Survival varies significantly by sex and race/ethnicity. Controlling for receipt of drug therapy and diagnosed health throughout the period, women are 56% as likely to die as men (P<.01). Hispanics are almost 14% less likely to die each month relative to whites (relative hazard, 0.87), and blacks are 20% more likely to die than whites (relative hazard, 1.21).
Conclusions States need to investigate why women are less likely to receive antiretroviral drug therapies than men and to consider policies that might foster better access to antiretroviral therapies for women with acquired immunodeficiency syndrome because these efforts might yield even further reductions in mortality in women. Given the large reductions in mortality that accompany receipt of antiretroviral therapies, states need to foster policies that promote widespread use of new drug treatment protocols.
From the Department of Economics, Vanderbilt University, Nashville, Tenn (Dr Anderson), and Georgetown Public Policy Institute, Georgetown University, Washington, DC (Dr Mitchell).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Longitudinal Relationships Between Use of Highly Active Antiretroviral Therapy and Satisfaction With Care Among Women Living With HIV/AIDS
Burke-Miller et al.
Am. J. Public Health 2006;96:1044-1051.
ABSTRACT
| FULL TEXT
Genital Dysplasia in Women Infected with Human Immunodeficiency Virus
Taylor et al.
J Am Board Fam Med 2004;17:108-113.
ABSTRACT
| FULL TEXT
Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users
Wood et al.
CMAJ 2003;169:656-661.
ABSTRACT
| FULL TEXT
Human Immunodeficiency Virus Infection: A Focus on Women
Pakyz et al.
Journal of Pharmacy Practice 2003;16:170-181.
ABSTRACT
|
